The US health department announced policies that will allow for the compounding of 6 key peptides in US pharmacies.
|Articles|August 15, 2010
Drug Topics Special Supplement
With so many best-selling name-brand drugs coming off patent over the next few years, the market for generics should expand markedly. In Drug Topics' special generics supplement, pharmacists from around the country offer their views.
Advertisement
With so many best-selling name-brand drugs coming off patent over the next few years, the market for generics should expand markedly. In Drug Topics' special generics supplement, pharmacists from around the country offer their views.
To read that story and more,
Advertisement
Related to this article
New survey data add to the evidence regarding the safe and effective route of administering both COVID-19 and flu vaccines simultaneously.
This episode breaks down how PBMs conduct inventory audits, the sourcing and timing issues that trigger recoupments, and how pharmacies can prepare and push back.
In part 2 of our discussion with Kimberly Kue-Tsemo, PharmD, she addresses the emergence of technology and the nuances behind its actual capabilities.
In part 2, Allison Schneider, MPH, discusses PBM and 340B reform that could compound pharmacies’ burden amid ongoing Medicare drug price negotiations.
Researchers provide an update on the adverse events of special interest following patients who received 2024–2025 Pfizer-BioNTech COVID-19 vaccination.
Type 1 and type 2 diabetes reports emphasize areas where pharmacists can act now, including CGM, cardio-kidney therapies, and equitable patient access.
Kimberly Kue-Tsemo, PharmD, explores the current state of US pharmacy deserts amid ongoing reform, evolution in practice, and more.
Advertisement
Advertisement
Trending on Drug Topics
1
Updated Diabetes Consensus Shifts Focus from Glucose Control to Whole-Person Care
2
American Pharmacists Month: Pharmacy Deserts Growing in US Despite Rising Awareness
3
What the CLARITY Study Means for Counseling on Long-Acting HIV PrEP
4
Pharmacy Law Lowdown: Defending Against PBM Inventory Audits
5